SY-640 is an Acetamide derivative and has potent hepatoprotective effect. SY-640 reduces Propionibacterium acnes and Lipopolysaccharide-induced liver injury in mice[1][2].
SY-640 inhibits the number of liver-infiltrating cells and attenuates the increased expression of leukocyte function-associated antigen-1 on these cells[1].
SY-640 (Oral; 150 mg/kg; once daily for 7 days) significantly inhibits Propionibacterium acnes and Lipopolysaccharide-induced liver injury, but a single administration is without effect[1]. SY-640 (p.o.; 150 mg/kg; once daily for three days) significantly increases the liver microsomal cytochrome P-450 content and aminopyrine demethylase activity in mice. The hepatic microsomal aminopyrine demethylase activity is obviously inhibited two hours after oral administration of SY-640[2].
[1]. Y Tanaka, et al. Hepatoprotective effect of SY-640, a novel acetamide derivative, on Propionibacterium acnes and lipopolysaccharide-induced liver injury in mice. Arch Int Pharmacodyn Ther. Mar-Apr 1995;329(2):319-30. [2]. P F Li, et al. [Inhibitory effect of 2-(N-acetyl-methyl amino)-3',4'-methylenedioxyacetyl-aminophene(SY-640) on covalent binding of carcinogenic benzo(a)pyrene with mouse hepatocyte nuclear DNA]. Yao Xue Xue Bao. 1997 Sep;32(9):663-8.